Greenyn Biotechnology Co (ROCO:6846) EBIT: NT$196.9 Mil (TTM As of Dec. 2025)


ROCO:6846 Greenyn Biotechnology Co Ltd ROCO:6846
65 GF Score
Price NT$63.70
GF Value NT$66.84
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Greenyn Biotechnology Co EBIT?

Greenyn Biotechnology Co ROCO:6846 -0.47% 65 EBIT is NT$196.9 Mil as of Dec. 2025. GuruFocus rates ROCO:6846 with a GF Score™ of 65/100 and a GF Value™ of NT$66.84 (Fairly Valued). The stock has 7 warning signs investors should review.

Greenyn Biotechnology Co's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was NT$68.4 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$196.9 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Greenyn Biotechnology Co's annualized ROC % for the quarter that ended in Dec. 2025 was 26.45%. Greenyn Biotechnology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 43.87%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Greenyn Biotechnology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 13.25%.

Greenyn Biotechnology Co  (ROCO:6846) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Greenyn Biotechnology Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=243.212 * ( 1 - 21.17% )/( (658.256 + 791.688)/ 2 )
=191.7240196/724.972
=26.45 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2041.999 - 151.885 - ( 1231.858 - max(0, 206.742 - 1538.93+1231.858))
=658.256

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2109.409 - 164.211 - ( 1153.51 - max(0, 217.105 - 1484.643+1153.51))
=791.688

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Greenyn Biotechnology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=273.64/( ( (466.698 + max(98.351, 0)) + (575.6 + max(106.877, 0)) )/ 2 )
=273.64/( ( 565.049 + 682.477 )/ 2 )
=273.64/623.763
=43.87 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(86.784 + 183.041 + 22.756) - (151.885 + 0 + 42.345)
=98.351

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(108.96 + 177.529 + 22.816) - (164.211 + 0 + 38.217)
=106.877

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Greenyn Biotechnology Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=196.931/1486.154
=13.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Greenyn Biotechnology Co EBIT Related Terms

Greenyn Biotechnology Co EBIT Historical Data

* Premium members only.

The historical data trend for Greenyn Biotechnology Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Greenyn Biotechnology Co EBIT Chart

Greenyn Biotechnology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial 170.39 185.26 167.48 185.20 196.93

Greenyn Biotechnology Co Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.51 58.03 28.00 42.50 68.41

ROCO:6846 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Greenyn Biotechnology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Greenyn Biotechnology Co EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Greenyn Biotechnology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Greenyn Biotechnology Co's EV-to-EBIT falls into.


ROCO:6846
65GF Score
Greenyn Biotechnology Co Ltd ROCO:6846
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Greenyn Biotechnology Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$196.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$196.9 Mil mean?
Greenyn Biotechnology Co (ROCO:6846) has a EBIT of NT$196.9 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Greenyn Biotechnology Co.
Is Greenyn Biotechnology Co's EBIT too high?
Greenyn Biotechnology Co's current EBIT is NT$196.9 Mil. Overall, Greenyn Biotechnology Co has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Greenyn Biotechnology Co's EBIT compare to VRTX and REGN?
Greenyn Biotechnology Co's EBIT of NT$196.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Greenyn Biotechnology Co. Greenyn Biotechnology Co's current EBIT is NT$196.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Greenyn Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Greenyn Biotechnology Co (ROCO:6846) is currently considered Fairly Valued. The stock's GF Value™ is NT$66.84, compared to a current price of NT$63.70 — trading 4.7% below its estimated fair value. The current EBIT is NT$196.9 Mil. Greenyn Biotechnology Co's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Greenyn Biotechnology Co (ROCO:6846), the current EBIT is NT$196.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Greenyn Biotechnology Co (ROCO:6846) Overvalued in 2026?

Based on GuruFocus' analysis, Greenyn Biotechnology Co stock appears to be undervalued. The current stock price of NT$63.70 is trading 4.7% below its estimated GF Value™ of NT$66.84. GuruFocus considers Greenyn Biotechnology Co to be Fairly Valued.

Key valuation signals for ROCO:6846:

  • EBIT: NT$196.9 Mil
  • GF Value™: NT$66.84 vs. price of NT$63.70 (4.7% below fair value)
  • GF Score™: 65/100 with 7 warning signs

No single metric tells the full story. See the ROCO:6846 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Greenyn Biotechnology Co Business Description

Address No 43 Keya Road, 5th Floor, Daya District, Taichung, TWN
Greenyn Biotechnology Co Ltd is engaged in the business of health food raw materials production and sales of raw materials and production and sales of formula preparation.
65GF Score

Get the complete analysis for ROCO:6846

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$63.70
Price
NT$66.84
GF Value